3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
6
Thoracic
2
Other hematologic neoplasm
2
Myeloid
2
Dermatologic
2
Plasma cell
1
Other solid neoplasm
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Gastrointestinal Stromal Tumors
71
Neoplasm Metastasis
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Stomach Neoplasms
4
Sarcoma
4
Pancreatic Neoplasms
4
Neoplasms
3
Digestive System Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Primary Myelofibrosis
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Piebaldism
2
Myeloproliferative Disorders
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Leukemia, Myeloid, Acute
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hodgkin Disease
2
Gastrointestinal Neoplasms
2
Blast Crisis
2
Waldenstrom Macroglobulinemia
1
Uveal Melanoma
1
Thrombocytosis
1
Thrombocythemia, Essential
1
Sezary Syndrome
1
Interventions
pembrolizumab
1
Imatinib Mesylate
1
Histamine H2 Antagonists
1
HhAntag691
1
Famotidine
1
Cyclophosphamide
1
Blood Specimen Collection
1
Angptl4 protein, mouse
1
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Dermatofibrosarcoma
×
Imatinib Mesylate
×
Gastrointestinal
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled